[{"id":"pralsetinib","kind":"drug","name":"Pralsetinib","route":"/drugs/pralsetinib/","commit":"ad64caf371","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a fifth batch of approved products","file":"src/data/spikes/nsclc.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pralsetinib\" }]"}]},{"id":"pralsetinib","kind":"drug","name":"Pralsetinib","route":"/drugs/pralsetinib/","commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"class"},{"field":"props"},{"field":"management"},{"field":"food"},{"field":"source"}]},{"id":"pralsetinib","kind":"drug","name":"Pralsetinib","route":"/drugs/pralsetinib/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/nsclc.ts","type":"changed","fields":[{"field":"tldr","before":"\"The second selective RET pill for lung cancer, less used than selpercatinib after a change of owner and label.\"","after":"\"Pralsetinib is the second selective RET pill for lung cancer, less used than selpercatinib after a change of owner and label.\""}]}]